


IARC Handbooks of Cancer Prevention



International Agency for Research on Cancer  
World Health Organization

# Breast Cancer Screening



IARC Press  
2002

IARC Handbooks of Cancer Prevention

**Volume 7**

**Breast Cancer Screening**

**IARC Handbooks of Cancer Prevention**  
**Programme Head: Harri Vainio**

**Volume 7: Breast Cancer Screening**

|                           |   |
|---------------------------|---|
| Editors:                  | Harri Vainio, M.D., Ph.D.<br>Franca Bianchini, Ph.D   |
| Technical editor:         | Elisabeth Heseltine, M.Sc.  |
| Bibliographic assistance: | Agnès Meneghel<br>Brigitte Kajo   |
| Photographic assistance:  | Georges Mollon/Pascale Rousson  |
| Layout:                   | Josephine Thévenoux   |
| Printed by:               | LIPS, Lyon, France  |
| Publisher:                | IARCPress<br>International Agency for Research on Cancer<br>150 cours Albert Thomas, 69372 Lyon, France<br>Tel. +33 4 72 73 84 85<br>Fax. +33 4 72 73 83 19 |



WORLD HEALTH ORGANIZATION  
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

# **IARC Handbooks of Cancer Prevention**

**Volume 7**

## **Breast Cancer Screening**

**IARC*Press***  
**Lyon, 2002**

Published by the International Agency for Research on Cancer,  
150 cours Albert Thomas, F-69372 Lyon cedex 08, France

© International Agency for Research on Cancer, 2002

Distributed by Oxford University Press, Walton Street, Oxford, OX2 6DP, UK (Fax: +44 1865 267782) and in the USA by  
Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA (Fax: +1 919 677 1303).

All IARC publications can also be ordered directly from IARCPress

(Fax: +33 4 72 73 83 02; E-mail: [press@iarc.fr](mailto:press@iarc.fr))

and in the USA from IARCPress, WHO Office, Suite 480, 1775 K Street, Washington DC, 20006

Publications of the World Health Organization enjoy copyright protection in  
accordance with the provisions of Protocol 2 of the Universal Copyright Convention.

All rights reserved.

The designations used and the presentation of the material in this publication do not imply the  
expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization  
concerning the legal status of any country, territory, city, or area or of its authorities,  
or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply  
that they are endorsed or recommended by the World Health Organization in preference to others  
of a similar nature that are not mentioned. Errors and omissions excepted,  
the names of proprietary products are distinguished by initial capital letters.

The authors alone are responsible for the views expressed in this publication.

The International Agency for Research on Cancer welcomes requests for permission to  
reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed  
to the Communications Unit, International Agency for Research on Cancer,  
which will be glad to provide the latest information on any changes made to the text, plans for new  
editions, and reprints and translations already available.

### **IARC Library Cataloguing in Publication Data**

Breast Cancer Screening/

IARC Working Group on the Evaluation of  
Cancer-Preventive Strategies (2002 : Lyon, France)

(IARC handbooks of cancer prevention ; 7)

1. Breast Neoplasms - prevention & control 2. Mass Screening I, IARC Working  
Group on the Evaluation of Cancer-Preventive Strategies II. Series

ISBN 92 832 3007 8

(NLM Classification: W1)

ISSN 1027-5622

Printed in France

## International Agency For Research On Cancer

The International Agency for Research on Cancer (IARC) was established in 1965 by the World Health Assembly, as an independently financed organization within the framework of the World Health Organization. The headquarters of the Agency are in Lyon, France.

The Agency conducts a programme of research concentrating particularly on the epidemiology of cancer and the study of potential carcinogens in the human environment. Its field studies are supplemented by biological and chemical research carried out in the Agency's laboratories in Lyon and, through collaborative research agreements, in national research institutions in many countries. The Agency also conducts a programme for the education and training of personnel for cancer research.

The publications of the Agency contribute to the dissemination of authoritative information on different aspects of cancer research. Information about IARC publications, and how to order them, is available via the Internet at: <http://www.iarc.fr/>

This publication represents the views and opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Strategies which met in Lyon, France, 5–12 March 2002



### Participants and members of the secretariat:

*First row from left:* T. Kuroishi, M. Blettner, F. Bianchini, M. Hakama, P. Dean, B. Armstrong, P. Pisani, S. Robles, J. Thévenoux. *Middle row:* E. Suonio, K. Straif, C. Partensky, S. Taplin, E. Heseltine, C. Baines, J. Hall, I. Andersson, G. Welsch, D. Thomas, N. Segnan, A. B. Miller, A. Krickler, H. Sancho-Garnier, S. Redman, L. Nyström. *Back row:* H. Vainio, S. Narod, H. de Koning, A. Ullrich, J. Tyczynski, E. Weiderpass-Vainio, N. Day, L. Irwig. (Participants missing from photo: V. Beral, I. Ellis and R. Blanks)

## **Note to the Reader**

Anyone who is aware of published data that may influence any consideration in these *Handbooks* is encouraged to make the information available to the Unit of Chemoprevention, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France

Although all efforts are made to prepare the *Handbooks* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Chemoprevention, so that corrections can be reported in future volumes.

## **Acknowledgements**

We would like to acknowledge generous support from the Foundation for Promotion of Cancer Research, Japan (2nd Term Comprehensive 10-Year Strategy for Cancer Control), and from the German Federal Ministry for Health.

# Contents

|  |      |   |    |
|--|------|---|----|
| List of participants   | xi   | <b>Other and emerging imaging techniques</b> . . . . .                        | 34 |
| Preface  | xiii | Digital mammography . . . . .   | 34 |
| <b>1. Breast cancer and screening</b>  |      | Ultrasonography . . . . .   | 36 |
| <b>The world-wide burden of breast cancer</b> . . . . .  | 1    | Magnetic resonance imaging . . . . .  | 36 |
| <b>Breast cancer biology, pathology and natural history as related to screening</b> . . . . .            | 4    | Positron emission tomography . . . . .  | 37 |
| Barriers to understanding of early cancers . . . . .   | 5    | Scintimammography . . . . .   | 38 |
| Benign breast disease . . . . .  | 5    | Electrical impedance imaging . . . . .  | 38 |
| Carcinoma in situ . . . . .  | 6    | Other techniques . . . . .  | 38 |
| Invasive carcinoma . . . . .   | 9    | <b>Clinical breast examination</b> . . . . .                                  | 39 |
| Can a patient be 'cured' of breast cancer ? . . . . .  | 16   | Technique . . . . .   | 39 |
| Diagnosis and treatment . . . . .  | 16   | Training . . . . .  | 41 |
| <b>Screening for breast cancer: Conceptual considerations</b> . . . . .                                  | 17   | Maintenance of standards . . . . .  | 42 |
| General definitions . . . . .  | 18   | Costs and potential harms . . . . .   | 43 |
| Positive predictive value, specificity and the issue of over-diagnosis . . . . .                         | 20   | Other issues . . . . .  | 43 |
| Cancers detected at screening, interval cancers and distribution of lead time and sojourn time . . . . . | 20   | <b>Breast self-examination</b> . . . . .                                      | 43 |
| Period screening: Length bias and the unbiased set . . . . .   | 20   | Technique . . . . .   | 43 |
| A more complex view of cancer . . . . .  | 21   | Training . . . . .  | 44 |
| <b>Evaluation of screening for breast cancer</b> . . . . .   | 22   | Maintenance of standards . . . . .  | 45 |
| <b>2. Screening techniques</b>   |      | Mechanisms for improving breast self-examination . . . . .                    | 45 |
| <b>Screening mammography</b> . . . . .   | 25   | Costs and potential harms . . . . .   | 46 |
| X-ray equipment . . . . .  | 25   | Other issues . . . . .  | 46 |
| Radiation dose . . . . .   | 28   | <b>3. Use of breast cancer screening</b>                                      |    |
| Quality control . . . . .  | 28   | <b>Delivery and uptake of screening</b> . . . . .                             | 47 |
| Sensitivity and specificity . . . . .  | 28   | Europe . . . . .  | 48 |
| Host factors that affect sensitivity . . . . .   | 32   | Americas . . . . .  | 54 |
| One versus two views . . . . .   | 33   | Oceania and Asia . . . . .  | 64 |
| Double reading . . . . .   | 34   | <b>Behavioural factors and the longer-term success of screening</b> . . . . . | 72 |
|  |      | Information and understanding . . . . .                                       | 72 |
|  |      | Psychological consequences of participation in screening . . . . .            | 74 |
|  |      | Encouraging participation in screening . . . . .                              | 74 |



## 4. Efficacy of screening

### Methodological and analytical issues in

|  |    |
|--|----|
| <b>assessing efficacy</b> .....  | 87 |
| Issues in evaluating the efficacy of screening .....                                 | 87 |
| Use of randomized controlled trials in evaluation of screening .....                 | 88 |
| Use of cohort (observational) and case-control studies in evaluating screening ..... | 91 |

### Efficacy of screening by conventional

|  |     |
|--|-----|
| <b>mammography</b> .....                     | 91  |
| Randomized trials .....                      | 91  |
| Cohort and nested case-control studies ..... | 101 |
| Quasi-experimental study .....               | 102 |

### Efficacy of screening by clinical breast

|                          |     |
|--------------------------|-----|
| <b>examination</b> ..... | 102 |
|--------------------------|-----|

### Efficacy of screening by breast self-

|   |     |
|---|-----|
| <b>examination</b> .....                        | 107 |
| Randomized trials .....                         | 107 |
| Cohort studies .....                            | 108 |
| Case-control studies .....                      | 110 |
| Studies of survival .....                       | 110 |
| Studies of extent of disease at diagnosis ..... | 111 |

### Efficacy of screening women at high risk

|                                  |     |
|----------------------------------|-----|
| .....                            | 113 |
| Radiation sensitivity .....      | 115 |
| Tumour factors .....             | 115 |
| Family history .....             | 115 |
| BRCA1 and BRCA2 .....            | 116 |
| Magnetic resonance imaging ..... | 117 |

## 5. Effectiveness of screening

### Has screening been implemented in accordance with the results of screening trials?

|                                   |     |
|-----------------------------------|-----|
| .....                             | 119 |
| Methods of invitation .....       | 119 |
| Screening processes .....         | 119 |
| Age range .....                   | 120 |
| Screening interval .....          | 120 |
| Mammography .....                 | 120 |
| Clinical breast examination ..... | 121 |
| Breast self examination .....     | 121 |

### Indicators for monitoring and evaluating the effectiveness of screening programmes

|   |     |
|---|-----|
| .....   | 121 |
| Origins of indicators of effectiveness of screening .....                   | 122 |
| Performance indicators .....  | 123 |
| Mortality from and screening for breast cancer in different countries ..... | 129 |
| Alternative measures of effect on mortality .....                           | 132 |
| Balance between false-positive and false-negative results .....             | 133 |
| Conclusion .....  | 134 |

### Hazards (risks) of screening

|  |     |
|--|-----|
| .....  | 135 |
| Occurrence and consequences of false-positive results in mammography ..... | 135 |
| Overdiagnosis .....  | 144 |
| Reservoir of potentially detectable breast cancer ..                       | 147 |
| Ductal carcinoma in situ .....   | 148 |
| Early mortality from breast cancer .....                                   | 150 |
| Risk for breast cancer induced by radiation .....                          | 150 |

## 6. Cost-effectiveness of population-based breast cancer screening

### Cost-effectiveness analysis: What and why?

|                                   |     |
|-----------------------------------|-----|
| .....                             | 157 |
| Published analyses .....          | 157 |
| Application of strict rules ..... | 158 |

### Elements of cost-effectiveness

|                                     |     |
|-------------------------------------|-----|
| .....                               | 158 |
| Effectiveness .....                 | 158 |
| Unfavourable effects .....          | 159 |
| Costs .....                         | 161 |
| Discounting effects and costs ..... | 162 |

### Modelling for policy decisions

|   |     |
|---|-----|
| .....   | 163 |
| Policy decisions on age categories to be screened ..... | 164 |
| Policy decisions on screening interval .....            | 164 |
| Policy decisions on high-risk groups .....              | 165 |
| Policy decisions on recall or referral .....            | 165 |

### Participation

|       |     |
|-------|-----|
| ..... | 165 |
|-------|-----|

### Cost-effectiveness in practice

|                          |     |
|--------------------------|-----|
| .....                    | 165 |
| Quality of life .....    | 166 |
| Cost .....               | 168 |
| Cost-effectiveness ..... | 168 |

|  |     |  |     |
|--|-----|--|-----|
| <b>Limitations of cost–effectiveness analysis</b> . . . . .  | 168 | <b>Overall evaluation</b> . . . . .  | 179 |
| Practical limitations . . . . .  | 168 | Effect of screening with mammography on mortality<br>from breast cancer . . . . .                      | 179 |
| Gaps in knowledge . . . . .  | 169 | Influence of inter-screening interval on effect of<br>screening by mammography . . . . .               | 179 |
| New developments . . . . .   | 169 | Effect of breast screening by clinical breast<br>examination on mortality from breast cancer . . . . . | 180 |
| <b>7. Summary</b>  |     | Effect of breast screening by breast self-<br>examination on mortality from breast cancer . . . . .    | 180 |
| <b>Breast cancer and screening</b> . . . . .   | 171 | Effectiveness in practice of breast cancer<br>screening with mammography . . . . .                     | 180 |
| World-wide burden . . . . .  | 171 | Adverse effects of breast screening  |     |
| Biology, pathology and natural history . . . . .   | 171 | Cost–effectiveness of a programme of screening<br>with mammography . . . . .                           | 181 |
| Conceptual considerations . . . . .  | 171 | Implications for public health . . . . .   | 181 |
| <b>Screening techniques</b> . . . . .  | 171 | <b>9. Recommendations</b>  |     |
| Screening mammography . . . . .  | 171 | <b>Research recommendations</b> . . . . .  | 183 |
| Other and emerging imaging techniques . . . . .  | 172 | Improving conventional mammography . . . . .   | 183 |
| Clinical breast examination . . . . .  | 172 | Implementing mammographic screening<br>programmes . . . . .  | 183 |
| Breast self-examination . . . . .  | 172 | Accuracy of mammographic screening . . . . .   | 183 |
| <b>Use of breast cancer screening</b> . . . . .  | 172 | Clinical breast examination . . . . .  | 183 |
| Delivery and uptake of screening . . . . .   | 172 | Breast self-examination . . . . .  | 184 |
| Behavioural considerations in screening<br>participation . . . . .                                       | 173 | Consequences of diagnosis of breast cancer . . . . .   | 184 |
| <b>Efficacy of screening</b> . . . . .   | 173 | Biology of breast tumours in relation to screening   | 184 |
| Methodological and analytical issues in assessing<br>efficacy . . . . .                                  | 173 | New techniques . . . . .   | 185 |
| Conventional screening mammography . . . . .   | 173 | Women at high risk . . . . .   | 185 |
| Clinical breast examination . . . . .  | 174 | <b>Public health recommendations</b> . . . . .   | 186 |
| Breast self-examination . . . . .  | 174 | Information systems . . . . .  | 186 |
| Women at high-risk . . . . .   | 174 | Implementation of mammographic screening<br>programmes . . . . .                                       | 186 |
| <b>Effectiveness of population-based screening</b> . . . . .   | 175 | <b>References</b> . . . . .  | 187 |
| Implementation of population-based screening in<br>accordance with results of screening trials . . . . . | 175 | <b>Glossary</b> . . . . .  | 219 |
| Indicators of the effectiveness of population-based<br>screening programmes . . . . .                    | 175 | <b>Working Procedures</b> . . . . .  | 223 |
| Hazards of screening . . . . .   | 176 | <b>Sources of figures</b> . . . . .  | 229 |
| <b>Cost-effectiveness of population-based<br/>screening</b> . . . . .                                    | 176 |  |     |
| <b>8. Evaluation</b>   |     |  |     |
| <b>Evaluation of the efficacy of breast cancer<br/>screening</b> . . . . .                               | 179 |  |     |

# List of participants

## **I. Andersson**

Department of Diagnostic Radiology  
Malmö University Hospital  
Malmö  
Sweden

## **B. Armstrong (Chairman)**

Edward Ford Building A27  
University of Sydney  
Sydney  
NSW 2006  
Australia

## **C. Baines**

Department of Public Health Sciences  
University of Toronto  
Toronto  
Ontario M5S 1A8  
Canada

## **V. Beral**

Imperial Cancer Research Fund  
Cancer Epidemiology Unit  
University of Oxford  
Gibson Building  
Radcliffe Infirmary  
Oxford OX2 6HE  
United Kingdom

## **R. Blanks**

Institute of Cancer Research  
Royal Cancer Hospital  
Cancer Screening Evaluation Unit  
Sutton  
Surrey SM2 5NG  
United Kingdom

## **M. Blettner**

Department of Epidemiology and  
Medical Statistics  
School of Public Health  
33501 Bielefeld  
Germany

## **N. Day**

Strangeways Research Laboratory  
University of Cambridge  
Cambridge CB1 8RN  
United Kingdom

## **P. Dean**

Department of Diagnostic Radiology  
University of Turku  
20521 Turku  
Finland

## **H.J. de Koning**

Department of Public Health  
Erasmus University Rotterdam  
3000 DR Rotterdam  
Netherlands

## **I. Ellis**

Faculty of Medicine and Health  
Sciences  
Division of Histopathology  
Nottingham City Hospital  
NHS Trust  
Nottingham NG5 1PB  
United Kingdom

## **S. Fletcher\***

Harvard Medical School  
Harvard Pilgrim Health Care  
Boston  
Massachusetts 02115  
USA

## **M. Hakama (Vice-Chairman)**

University of Tampere  
School of Public Health  
33014 Tampere  
Finland

## **L. Irwig**

Screening and Test Evaluation  
Program (STEP)  
Department of Public Health and  
Community Medicine  
University of Sydney  
Sydney  
NSW 2006  
Australia

## **A. Kricker**

NHMRC  
National Breast Cancer Centre  
Kings Cross  
Sydney  
NSW  
Australia

## **T. Kuroishi**

Division of Epidemiology &  
Prevention  
Aichi Cancer Center Research  
Institute  
464-8681 Nagoya  
Japan

## **A.B. Miller**

Division of Clinical Epidemiology  
German Cancer Research Center  
69120 Heidelberg  
Germany

\*Unable to attend

**S. Narod**

The Centre for Research in Women's Health  
Toronto M5G 1N8  
Canada

**C. Nichols\***

Office of Science Planning and Assessment  
National Cancer Institute  
Bethesda  
Maryland 20892  
USA

**L. Nyström**

Department of Public Health and Clinical Medicine  
Unit of Epidemiology  
Umeå University  
901-85 Umeå  
Sweden

**S. Redman**

NHMRC  
National Breast Cancer Centre  
Kings Cross  
NSW  
Australia

**S. Robles**

Pan American Health Organization  
Regional Office of the World Health Organization  
HCP/HCN  
Washington DC 20037  
USA

**H. Sancho-Garnier**

EPIDAURE  
Centre Val d'Aurelle  
Parc Euromédecine  
34298 Montpellier  
France

**N. Segnan**

CPO Piemonte  
Cancer Prevention Centre  
Unit of Epidemiology  
10123 Torino  
Italy

**S. Taplin**

Group Health Cooperative  
Center for Health Studies  
Seattle  
Washington 98101-1448  
USA

**D.B. Thomas**

Fred Hutchinson Cancer Research Center  
Seattle  
Washington 98109-1024  
USA

**H.G. Welch**

Department of Medicine and Community and Family Medicine  
Dartmouth Medical School  
Hanover  
New Hampshire 03755  
USA

**Observer**

A. Ullrich  
WHO  
Geneva  
Switzerland

**Secretariat**

F. Bianchini  
J. Cheney  
J. Hall  
E. Heseltine (Lajarthé, 24290 St Léon-sur-Vézère, France)  
C. Partensky  
D.M. Parkin  
P. Pisani  
A. Sasco  
K. Straif  
L. Stayner  
E. Suonio  
J. Tyczynski  
H. Vainio  
E. Weiderpass-Vainio

**Technical assistance**

B. Kajo  
J. Mitchell  
C. Mogenet  
J. Thévenoux

\* Unable to attend

## Preface

# Why a Handbook on breast cancer screening ?

The scientific process of acquiring information about the efficacy of breast cancer screening was initiated in 1963, when Sam Shapiro and coworkers introduced the Health Insurance Plan study (Shapiro *et al.*, 1988a) in New York, USA, the first randomized controlled trial of the effect of mammography and clinical breast examination in reducing mortality from breast cancer. This study opened the era of randomized controlled trials for evaluation of screening techniques. Cancer screening techniques used before that, such as the Papanicolaou (Pap) smear, never underwent proper evaluation in randomized trials before their introduction as a means for population screening.

Randomized controlled trials have been criticized many times as expensive and slow to provide results. The Breast Cancer Detection Demonstration Project (Baker, 1982) in the USA was initiated to provide data on the efficacy of breast cancer screening rapidly, and the first results appeared in 1979, 3 years before publication of the results of the Health Insurance Plan study. Three more studies — in Malmö, Sweden (Andersson *et al.*, 1988), Edinburgh, Scotland (Roberts *et al.*, 1990) and in two Swedish counties (Tabár *et al.*, 1985) — were initiated 13–14 years after the beginning of the Health Insurance Plan study, and another three studies were initiated in 1980–82, in Canada (Miller *et al.*, 1992a,b) and in Stockholm (Frisell *et al.*,

1986) and Göteborg, Sweden (Bjurstam *et al.*, 1997). Thus, a number of randomized controlled trials, initiated in five different countries over a 20-year period, provide the basis for evidence in the field of mammographic screening.

Mammography was first officially introduced in a population-wide, organized screening programme in Iceland and in several districts in Sweden in 1987. The Netherlands and several regions of Canada followed in 1988, and Finland in 1989. In 1988, the American Cancer Society and the Preventive Services Task Force established policies in favour of screening for breast cancer in the USA (US Preventive Task Force, 1996). In contrast to the policies in other countries, that in the USA emphasized a triple approach, involving breast self-examination, clinical breast examination and mammography. The Europe Against Cancer programme simultaneously initiated a series of pilot screening programmes in several countries in Europe (Commission of the European Communities, 1996) in order to develop expertise in planning and running high-quality population-based screening programmes before their incorporation into national policy. In the early 1990s, national screening programmes were initiated in Australia and the United Kingdom, and these were followed by organized programmes in several states of the USA, in Israel and, later, in France. Germany and

Switzerland were among the last western countries to join the international trend, with plans to introduce national screening at the beginning of the twenty-first century.

Experience in large-scale mammographic screening by the mid-1990s, and the availability of data on more recent follow-up from the trials, led to discussion about the value of mammographic screening for women under the age of 50. Even on the basis of the same scientific evidence, few countries have established the same breast cancer screening policy. The policies differ with respect to the target age group to be screened, the frequency of screening, the number of mammographic views to be taken and the screening modalities. In Japan, the policy was based on clinical breast examination until recently, when it was decided to add mammography.

In spite of the vast amount of information available from several randomized trials, some doubt has recently been cast on the value of breast cancer screening in reducing mortality from breast cancer (Gotzsche & Olsen, 2000; Olsen & Gotzsche, 2001). In this volume, the relevant published studies are thoroughly reassessed, together with the newest data, either recently published or in press, according to the procedures and guidelines followed in the Handbooks (see pp. 223)